Prosthetic Joint Infection Clinical Trial
Official title:
A Phase 1, Blinded, Single Ascending Dose Study to Evaluate Safety, Pharmacokinetics, and Activity of TRL1068 in Subjects With Prosthetic Joint Infection of the Knee or Hip, Undergoing Primary Two Stage Exchange Arthroplasty
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens. This initial study is designed to assess overall safety and pharmacokinetics (PK) of TRL1068. The overall goal of the development program is to demonstrate that TRL1068 can facilitate effectiveness of a single stage joint replacement or preservation of the original infected prosthetic joint in a substantial proportion of patients with PJI.
Approximately 75% of all clinically significant human infections are estimated to be biofilm-related. Prosthetic joint infections are a classical example of difficult to eradicate infections associated with biofilm. Most Prosthetic Joint Infection (PJI) cases are caused by staphylococcal species (~70%) with an increasing number being antibiotic-resistant (MRSA). In the US, two-stage revision is the standard of care for replacement of an infected prosthetic joint, and is associated with substantial costs and prolonged immobility. TRL1068 is a fully human antibody that has been shown in pre-clinical studies to disrupt biofilm. TRL1068 targets a highly conserved epitope on the DNABII family of bacterial DNA binding proteins that includes histone-like (HU) and integration host factor (IHF) proteins of clinically relevant Gram-positive and Gram-negative bacteria. The DNABII epitope bound by TRL1068 has no homologs in the human proteome. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04067843 -
Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
|
N/A | |
| Enrolling by invitation |
NCT05247281 -
NGS vs Culture Outcomes for Treatment of PJI
|
N/A | |
| Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02801253 -
Cohort of Prosthetic Joint Infections
|
||
| Completed |
NCT03694925 -
Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
|
||
| Completed |
NCT03721328 -
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
|
Phase 2 | |
| Withdrawn |
NCT04787250 -
Bacteriophage Therapy in Patients With Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03307109 -
Quality of Life in Patients Having a Prosthetic Joint Infection
|
||
| Recruiting |
NCT04661345 -
Identification of Molecular Marker of Coagulase-negative Staphylococci for the Diagnosis of Prosthetic Joint Infections
|
||
| Recruiting |
NCT02805803 -
Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.
|
N/A | |
| Completed |
NCT02413034 -
The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures
|
N/A | |
| Recruiting |
NCT03784807 -
New Strategies for Biofilm Related Infections
|
||
| Completed |
NCT04662632 -
Abbreviated Protocol for Two-Stage Exchange
|
Phase 2 | |
| Not yet recruiting |
NCT04390607 -
Leukocyte Esterase Sensor Test
|
||
| Recruiting |
NCT04650607 -
Phage Safety Cohort Study
|
||
| Active, not recruiting |
NCT04946500 -
Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
|
||
| Recruiting |
NCT04762706 -
Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot.
|
N/A | |
| Withdrawn |
NCT05269134 -
Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)
|
Phase 2 | |
| Not yet recruiting |
NCT05239312 -
Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
|
||
| Completed |
NCT04294862 -
Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty
|
Phase 1 |